The Endocrine Society is urging the Senate to pass the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act. This legislation would make insulin more affordable by capping insulin costs at $35/month for people with private insurance; ensuring that insulin rebates and discounts, which are normally collected by pharmacy benefit managers (PBMs), are passed down to patients; and encouraging competition from generic and biosimilar insulins.  

The Endocrine Society has advocated for Congress to address insulin affordability for years. In 2022, we successfully advocated for the Inflation Reduction Act, which capped insulin costs for Medicare beneficiaries. However, we continue to call on Congress to pass legislation that addresses insulin affordability for those with private insurance. It's imperative that you – the constituent – remind your Senators that addressing insulin affordability is a top priority. 

Join our campaign today! 

Please enter your personal contact information (not your institution address) to identify your correct members of Congress. 

After selecting "Next" you will be shown a template letter that we created. We encourage you to personalize the letter with why addressing insulin affordability is important to you and your patients. However, you may also send the letter as written. 

If you work at a state university and are not sure if you can participate, please check with your institution's federal relations office. 

Additional Resources

Endocrine Society Position Statement on Insulin Affordability

Social Media Campaign

The Endocrine Society is urging the Senate to pass the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act. This legislation would make insulin more affordable by capping insulin costs at $35/month for people with private insurance; ensuring that insulin rebates and discounts, which are normally collected by pharmacy benefit managers (PBMs), are passed down to patients; and encouraging competition from generic and biosimilar insulins.  

The Endocrine Society has advocated for Congress to address insulin affordability for years. In 2022, we successfully advocated for the Inflation Reduction Act, which capped insulin costs for Medicare beneficiaries. However, we continue to call on Congress to pass legislation that addresses insulin affordability for those with private insurance. It's imperative that you – the constituent – remind your Senators that addressing insulin affordability is a top priority. 

Join our campaign today! 

Please enter your personal contact information (not your institution address) to identify your correct members of Congress. 

After selecting "Next" you will be shown a template letter that we created. We encourage you to personalize the letter with why addressing insulin affordability is important to you and your patients. However, you may also send the letter as written. 

If you work at a state university and are not sure if you can participate, please check with your institution's federal relations office. 

Additional Resources

Endocrine Society Position Statement on Insulin Affordability

Social Media Campaign